Market research
K3P.F Kiadis Pharma N.V
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 220M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 5.18
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 220M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 5.18
About
About Kiadis Pharma N.V
Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.
Research context
Kiadis Pharma N.V appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the K3P.F discussion.
5 years, 7 months ago
Kiadis Pharma N.V is currently in a long term uptrend where the price is trading 16.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Kiadis Pharma N.V gets an overall score of 2/5.